AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE

Key Points

• Bank of America increased its AngioDynamics stake by 262.7% in the first quarter, reaching 503,640 shares valued at approximately $5.7 million. Institutional investors collectively own 89.43% of the company.
• AngioDynamics reported quarterly revenue of $86.61 million and an adjusted loss of $0.07 per share, beating analyst expectations for both metrics. The company maintains negative margins and expects fiscal 2027 EPS between negative $0.29 and negative $0.24.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $19.50; recent targets range from $16 to $20. The stock opened at $15.78, near its 52-week high of $16.29.

Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 262.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763 shares during the quarter. Bank of America Corp DE owned approximately 1.22% of AngioDynamics worth $5,726,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Franklin Resources Inc. boosted its position in AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier's stock worth $621,000 after acquiring an additional 1,076 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 1,199 shares during the last quarter. Deutsche Bank AG raised its holdings in AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier's stock valued at $457,000 after acquiring an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics in the 4th quarter worth approximately $27,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of AngioDynamics by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier's stock worth $569,000 after purchasing an additional 2,263 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Stock Performance

ANGO opened at $15.78 on Friday. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29. The stock has a market capitalization of $652.22 million, a PE ratio of -18.14 and a beta of 0.33. The business's 50 day moving average price is $14.26 and its 200 day moving average price is $12.22.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analysts' expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. As a group, equities research analysts forecast that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the company's stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company's stock, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANGO shares. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 22nd. HC Wainwright boosted their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Canaccord Genuity Group upped their target price on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Zacks Research lowered AngioDynamics from a "hold" rating to a "strong sell" rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $19.50.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source